Roald Torp

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy

Martine De Vos, Édouard Louis, Jørgen Jahnsen et al. · Inflammatory Bowel Diseases · 2013 · 204 citations

Medicine, Clinical Sciences, Internal Medicine +14

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll et al. · JAMA · 2021 · 160 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls

Lars‐Petter Jelsness‐Jørgensen, Tomm Bernklev, Magne Henriksen et al. · Inflammatory Bowel Diseases · 2010 · 147 citations · Full text

Veterinary Medicine, Chronic Disease Control, Gastroenterology +12

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, J. Sexton et al. · Journal of Internal Medicine · 2019 · 122 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13